Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for acute manic episodes in bipolar I disorder
NCT03257865Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in bipolar I disorder (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Young-Mania Rating Scale at 3 weeks. Started Sep 2017; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT03257865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257865.